Eva Wardelmann
Impact in
- Gastroenterology top 0.05%
- Gastrointestinal Tumor Research and Treatment
- Pulmonary and Respiratory Medicine top 0.2%
- Sarcoma Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
Papers in
-
- Gastrointestinal Tumor Research and Treatment 89
-
- Sarcoma Diagnosis and Treatment 101
- Gastric Cancer Management and Outcomes 25
- Metastasis and carcinoma case studies 12
- Co-authors
- Christiane Katharina Kuhl (11 shared papers)C Leutner (10 shared papers)Hans Heinz Schild (10 shared papers)Sabine Merkelbach-Bruse (42 shared papers)Walther Christian Kuhn (6 shared papers)Simone Schrading (4 shared papers)Peter Hohenberger (30 shared papers)Sven Klaschik (3 shared papers)
- Journals
- European Journal of Cancer (17 papers)Clinical Cancer Research (12 papers)Oncotarget (10 papers)Annals of Oncology (10 papers)International Journal of Cancer (9 papers)
- Partner nations
- GermanyUnited StatesItaly
In The Last Decade
Eva Wardelmann
314 papers receiving 16.8k citations
Eva Wardelmann's Hit Papers
Peers
Comparison fields: 5 of 150
- Gastroenterology 4.3k
- Pulmonary and Respiratory Medicine 6.2k
- Rheumatology 1.8k
- Radiology, Nuclear Medicine and Imaging 2.5k
- Pathology and Forensic Medicine 1.9k
Countries citing papers authored by Eva Wardelmann
This map shows the geographic impact of Eva Wardelmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Wardelmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Wardelmann more than expected).
Fields of papers citing papers by Eva Wardelmann
This network shows the impact of papers produced by Eva Wardelmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Wardelmann. The network helps show where Eva Wardelmann may publish in the future.
Co-authors
The 25 scholars most cited alongside Eva Wardelmann, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 330 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2018 | 1096 |
| 2 | Dynamic Breast MR Imaging: Are Signal Intensity Time Course Data Useful for Differential Diagnosis of Enhancing Lesions? Hit paper breakdown → | 1999 | 1085 |
| 3 | Mammography, Breast Ultrasound, and Magnetic Resonance Imaging for Surveillance of Women at High Familial Risk for Breast Cancer Hit paper breakdown → | 2005 | 912 |
| 4 | One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor Hit paper breakdown → | 2012 | 779 |
| 5 | Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2018 | 598 |
| 6 | MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study Hit paper breakdown → | 2007 | 546 |
| 7 | 2000 | 447 | |
| 8 | Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2018 | 436 |
| 9 | NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial Hit paper breakdown → | 2019 | 434 |
| 10 | Sarcoma classification by DNA methylation profiling Hit paper breakdown → | 2021 | 388 |
| 11 | The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients Hit paper breakdown → | 2020 | 312 |
| 12 | 2006 | 309 | |
| 13 | 2017 | 272 | |
| 14 | 2015 | 210 | |
| 15 | 2003 | 190 | |
| 16 | 2015 | 172 | |
| 17 | 2010 | 169 | |
| 18 | HLA-G is a potential tumor marker in malignant ascites. | 2003 | 166 |
| 19 | 2005 | 156 | |
| 20 | 2005 | 149 |
About Eva Wardelmann
Eva Wardelmann is a scholar working on Gastroenterology, Pulmonary and Respiratory Medicine, Oncology, Rheumatology and Pathology and Forensic Medicine, having authored 330 papers that have together received 17.3k indexed citations. Recurring topics across this work include Sarcoma Diagnosis and Treatment (101 papers), Gastrointestinal Tumor Research and Treatment (89 papers), Gastrointestinal disorders and treatments (27 papers), Gastric Cancer Management and Outcomes (25 papers), Tumors and Oncological Cases (18 papers), Soft tissue tumor case studies (16 papers), Vascular Tumors and Angiosarcomas (13 papers) and Metastasis and carcinoma case studies (12 papers). The work is most often cited by research in Gastroenterology (4.3k citations), Pulmonary and Respiratory Medicine (6.2k citations), Rheumatology (1.8k citations), Radiology, Nuclear Medicine and Imaging (2.5k citations) and Pathology and Forensic Medicine (1.9k citations). Eva Wardelmann has collaborated with scholars based in Germany, United States and Italy. Frequent co-authors include Christiane Katharina Kuhl, C Leutner, Hans Heinz Schild, Sabine Merkelbach-Bruse, Walther Christian Kuhn, Simone Schrading, Peter Hohenberger, Sven Klaschik, Reinhard Büttner and Wolfgang Hartmann. Their work appears in journals such as European Journal of Cancer, Clinical Cancer Research, Oncotarget, Annals of Oncology and International Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.